Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.52 |
| ▸ | HTR1A | P08908 | 7/20 | 0.52 |
| ▸ | HTR6 | P50406 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10034989 | 0.87 | OPRL1 (0.44) | HTR2CSLC6A4 | |
| SCHEMBL5584146 | 0.86 | HTR2C (0.58) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL4886081 | 0.84 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL1765151 | 0.81 | SLC6A2 (0.55) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL17948231 | 0.81 | HTR2C (0.61) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL28464976 | 0.81 | PTGDR2 (0.48) | — | |
| Hydrochloric Acid SCHEMBL6075890 | 0.80 | SLC6A2 (0.54) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL4888125 | 0.80 | HTR2C (0.62) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3549827 | 0.80 | SLC6A2 (0.45) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3543969 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | HTR2C 31/4885SLC6A2 341/4885SLC6A4 612/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | HTR2C 31/4885SLC6A2 341/4885SLC6A4 612/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | HTR2C 31/4885SLC6A2 341/4885SLC6A4 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.